MyShare
Key factors
| sym | XTLB |
| exch | US |
| MCap | 5258.43K |
| Beta | 0.814 |
| EPS | -0.4 |
| Div date | 0000-00-00 |
Yesterday
| sym | XTLB |
| exch | US |
| close | 2.47 |
| 50 Day MA | 0.963 |
| 200 Day MA | 1.001 |
| 52 Week High | 1.54 |
| 52 Week Low | 0.75 |
| Target Price | 30.0 |
| Market Cap Mln | 5.258 |
Share statistics
| Shares Outstanding | 5449.06K |
| Shares Float | 413.25M |
| Percent Institutions | 4.569 |
| SharesShort | 6879.0 |
| Short Ratio | 2.1 |
| Shares Short Prior Month | 6799.0 |
| Short Percent | 1.020 |
Income
| EBITDA | -789.0K |
| Diluted Eps TTM | -0.4 |
| Quarterly Earnings Growth YOY | -75.9 |
earning
| Earnings Share | -0.4 |
Dividend
| Dividend Date | 2017-02-10 |
| Last Split Date | 2017-02-10 |
| Last Split Factor | 1:5 |
business
| Enterprise Value Ebitda | -1.75 |
| Book Value /share | 0.005 |
| Price Book MRQ | 1.895 |
| ReturnOnAssetsTTM | -0.13 |
| ReturnOnEquityTTM | -0.62 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Biotechnology |
| Gic Sector | Health Care |
| Gic Sub Industry | Biotechnology |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | US98386D3070 |
| Code | XTLB |
| CUSIP | 98386D307 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-02-09 |
| Home Category | ADR |
info
| Fiscal Year End | December |
| IPODate | 2005-09-01 |
| International Domestic | International Domestic |
| MostRecent Quarter | 2023-09-30 |
Contact
| Name | XTL Biopharmaceuticals Ltd ADR |
| Address | 5 Badner Street, Ramat Gan, Israel, 5218102 |
| Country Name | USA |
| Phone | 972 3 611 6600 |
| Web URL | https://www.xtlbio.com |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.